SynthesisFrontiers in immunology2025
Circulating cell adhesion molecules as biomarkers in inflammatory bowel disease: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular determinants of thromboinflammatory activation in inflammatory bowel disease.Journal of molecular medicine (Berlin, Germany) · 2026Review
- A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?Current opinion in lipidology · 2026Review
- Extracellular Vesicles in the Gut-Vascular-Brain Axis: A Missing Mechanistic Link Between IBD and Stroke Risk.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Endothelial dysfunction is a recognized component of the pathogenesis and clinical course of inflammatory bowel disease (IBD). Measurement of soluble forms of cell adhesion molecules (CAMs) may reflect the extent of endothelial injury and serve as potential biomarkers of disease activity. We conducted a systematic review and meta-analysis of studies reporting soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVCAM-1), mucosal addressin cell adhesion molecule-1 (sMAdCAM-1), and selectins (sE-selectin, sP-selectin, and sL-selectin) in patients with IBD and healthy controls, or in comparable IBD subgroups defined by disease activity or type. Methods: We systematically searched PubMed, Embase, Web of Science, and Scopus from inception to June 15, 2025. Risk of bias was assessed using a modified Newcastle-Ottawa Scale. Results: Twenty-six studies met the inclusion criteria. Compared with healthy controls, patients with IBD showed higher levels of sICAM-1 (SMD 1.38, 95% CI 0.51 to 2.25, p=0.002) and sE-selectin (SMD 0.35, 95% CI 0.09 to 0.61, p=0.008). In subgroup analyses, this association persisted for sICAM-1 in both Crohn's disease (CD) (SMD 1.89, 95% CI 0.15 to 3.62, p=0.033) and ulcerative colitis (UC) (SMD 0.95, 95% CI 0.25 to 1.64, p=0.008), and for sE-selectin only in CD (SMD 0.43, 95% CI 0.04 to 0.82, p=0.032). When comparing active and inactive disease, higher sICAM-1 levels were observed in the active group (SMD 0.75, 95% CI 0.38 to 1.12, p<0.001), while no significant differences were found for other CAMs. No differences in levels of these molecules were observed between CD and UC. Conclusions: Circulating CAMs, particularly sICAM-1 and sE-selectin, are elevated in IBD patients, supporting a role of endothelial injury in disease pathogenesis. Among these, sICAM-1 shows potential as a biomarker for distinguishing active from inactive disease. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251088622.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.